Categories
News

Doctors de Sharad Kelkar se estrenará pronto en JioCinema: ¿Cuándo verlo en línea?

[ad_1]

Sharad Kelkar, una personalidad destacada de la televisión y el cine indios, está listo para desempeñar el papel principal en la próxima serie web 'Doctors'. Este programa, dirigido por Saher Redha, explora los desafíos que enfrentan los profesionales médicos en su exigente vida profesional. Según los informes, Doctors se estrenará el 27 de diciembre de 2024 exclusivamente en JioCinema. La serie destaca las complejidades de la profesión médica y combina drama y suspenso para brindar una experiencia visual agradable.

Cuándo y dónde consultar a los médicos

A partir del 27 de diciembre, los médicos estarán disponibles en Cine Geo. Los suscriptores de los servicios premium de la plataforma pueden acceder a la serie. Los creadores de la serie han cautivado a los espectadores con destellos del programa, prometiendo profundizar en la vida del personal del ficticio Centro Médico Elizabeth Blackwell.

Tráiler oficial y argumento de los médicos.

El tráiler presenta a la audiencia lo que está en juego. ambiente Desde el hospital presenta las luchas y victorias de un equipo especializado de médicos. Sharad Kelkar interpreta a un médico entusiasta que motiva a sus colegas en situaciones difíciles, recordándoles los riesgos de vida o muerte de su profesión. Esta historia, escrita por Siddharth P. Malhotra, profundiza en las presiones físicas y mentales que enfrentan los médicos y destaca cómo sus exigentes funciones impactan su bienestar.

Actores y personal médico.

El elenco incluye a Sharad Kelkar, Harleen Sethi, Aamir Ali, Viraf Patel y Vivan Shah en los papeles principales. Producida por Siddharth P. Malhotra y Sapna Malhotra bajo Alchemy Films Pvt. Limitado. Limitado. En colaboración con Jio Studios, la serie está dirigida por Saher Reda.

[ad_2]

Source Article Link

Categories
Computers

Doctors Combined a Heart Pump and Pig Kidney Transplant in Breakthrough Surgery

[ad_1]

The kidney used in the latest NYU transplant was procured from a pig with a single genetic edit—the removal of a gene that produces a sugar known as alpha gal. This sugar appears on the surface of pig cells and seems to be responsible for rapid rejection in humans. The pig was engineered by Revivicor, a subsidiary of United Therapeutics Corporation.

Mandeep Mehra, a cardiologist and professor of medicine at Harvard Medical School, is excited by the NYU news. “It’s very innovative to combine the two,” he says, but the heart pump carries a risk of infection. Left ventricular assist devices require external batteries to power them. A wire comes out of the patient’s abdomen and connects to a controller and battery pack. “It’s that exit site that can be prone to infection,” he says.

Mehra says it also remains to be seen whether the single gene edit will be enough to prevent rejection and keep the kidney functioning for the long term. “The entire premise of gene editing was to overcome the immunological barrier,” he says.

Close up of surgeons in organ transplant surgery

PHOTOGRAPH: JOE CARROTTA FOR NYU LANGONE HEALTH

In the previous pig organ transplants in living patients, the animals had more modifications. The pig used for the heart transplants had 10 edits and the one used in Slayman’s procedure last month had 69. Yet with both Bennett’s and Faucett’s hearts, doctors noted signs of rejection. And even a week after Slayman’s surgery, his kidney showed early evidence of rejection—something his medical team hadn’t expected.

“The evolutionary distance between humans and pigs is 100 million years,” Mehra says. “Any gene editing needs to overcome that.”

The NYU’s team is taking a “less is more” approach with gene editing, Montgomery said, and instead relying on the pig’s thymus to help mediate the immune mismatch.

Pisano says she’s glad she took a chance on the procedure. She hopes she can leave the hospital so she can go shopping and play with her grandchildren. “The worst case scenario is that it doesn’t work,” she says, but even then she thinks it would be worthwhile. “It might work for the next person.”

[ad_2]

Source Article Link

Categories
Computers

He Got a Pig Kidney Transplant. Now Doctors Need to Keep It Working

[ad_1]

Other than rejection of the organ, one of the most common transplant complications is infection. Doctors have to strike a balance when prescribing immunosuppressive drugs: too low a dose can lead to rejection, while too much can make a patient vulnerable to infection. Immunosuppressants are powerful drugs that can cause a range of side effects, including fatigue, nausea, and vomiting.

Despite the deaths of the two pig heart recipients, Riella is optimistic about Slayman’s transplant. For one, he says, Slayman was relatively healthy when he underwent the surgery. He qualified for a human kidney but because of his rare blood type he would likely need to wait six to seven years to get one. The two individuals who received pig heart transplants were so ill that they didn’t qualify for a human organ.

In addition to close monitoring and traditional immunosuppressants, Slayman’s medical team is treating him with an experimental drug called tegoprubart, developed by Eledon Pharmaceuticals of Irvine, California. Given every three weeks via an IV, tegoprubart blocks crosstalk between two key immune cells in the body, T cells and B cells, which helps suppress the immune response against the donor organ. The drug has been used in monkeys that have received gene-edited pig organs.

Hospital patient

Photograph: Massachusetts General Hospital

“It’s pretty miraculous this man’s out of the hospital a couple of weeks after putting in a pig kidney,” says Steven Perrin, Eledon’s president and chief scientific officer. “I didn’t think we would be here as quickly as we are.”

Riella is also hopeful that the 69 genetic alterations made to the pig that supplied the donor organ will help Slayman’s kidney keep functioning. Pig organs aren’t naturally compatible in the human body. The company that supplied the pig, eGenesis, used Crispr to add certain human genes, remove some pig genes, and inactivate latent viruses in the pig genome that could hypothetically infect a human recipient. The pigs are produced using cloning; scientists make the edits to a single pig cell and use that cell to form an embryo. The embryos are cloned and transferred to the womb of a female pig so that her offspring end up with the edits.

“We hope that this combination will be the secret sauce to getting this kidney to a longer graft survival,” Riella says.

There’s debate among scientists over how many edits pig organs need to last in people. In the pig heart transplants, researchers used donor animals with 10 edits developed by United Therapeutics subsidiary Revivicor.

There’s another big difference between this procedure and the heart surgeries: If Slayman’s kidney did stop working, Riella says, he could resume dialysis. The pig heart recipients had no back-up options. He says even if pig organs aren’t a long-term alternative, they could provide a bridge to transplant for patients like Slayman who would otherwise spend years suffering on dialysis.

“We’ve gotten so many letters, emails, and messages from people volunteering to be candidates for the xenotransplants, even with all the unknowns,” Riella says. “Many of them are struggling so much on dialysis that they’re looking for an alternative.”

The Mass General team plans to launch a formal clinical trial to transplant edited pig kidneys in more patients. They received special approval from the US Food and Drug Administration for just one procedure. For now, though, their main focus is on keeping Slayman healthy.

[ad_2]

Source Article Link